TAPENTADOL LICONSA

Posology The dosing regimen should be individualised according to the severity of pain being treated, the previous treatment experience and the ability to monitor the patient. This product should be taken twice daily, approximately every 12 hours.

Adults Initiation of therapy Initiation of therapy in patients currently not taking opioid analgesics Patients should start treatment with single doses of 50 mg tapentadol as prolonged- release tablet administered twice daily. Initiation of therapy in patients currently taking opioid analgesics When switching from opioids to this product and choosing the initial dose, the nature of the previous medicinal product, administration and the mean daily dose should be taken into account.

This may require higher initial doses of this product for patients currently taking opioids compared to those not having taken opioids before initiating therapy with this product Titration and maintenance After initiation of therapy the dose should be titrated individually to a level that provides adequate analgesia and minimises undesirable effects under the close supervision of the prescribing physician.

Experience from clinical trials has shown that a titration regimen in increments of 50 mg tapentadol as prolonged-release tablet twice daily every 3 days was appropriate to achieve adequate pain control in most of the patients. Total daily doses of this product greater than 500 mg tapentadol have not yet been studied and are therefore not recommended.

2). 2). 2). This product should be used with caution in patients with moderate hepatic impairment. e. 50 mg tapentadol as prolonged-release tablet, and not be administered more frequently than once every 24 hours. At initiation of therapy a daily dose greater than 50 mg tapentadol as prolonged-release tablet is not recommended.

2). 2). Elderly Patients (persons aged 65 years and over) In general, a dose adaptation in elderly patients is not required. 2). Paediatric population Dose recommendation for children is dependent on age and body weight. 5 mg per kg body weight given every 12 hours.

Nevertheless, a starting dose of 50 mg should not be exceeded. From the available tablet strengths, either 25 mg or 50 mg should be considered as starting doses. Initiation of therapy in patients currently taking opioid analgesics When switching from opioids to this product and choosing the initial dose, the nature of the previous medicinal product, administration and the mean daily dose should be taken into account.

This may require higher initial doses of this product for patients currently taking opioids compared to those not having taken opioids before initiating therapy with this product. Titration and maintenance After initiation of therapy the dose should be titrated individually to a level that provides adequate analgesia and minimizes side effects under the close supervision of the prescribing physician with dose increments of 25 mg for patients less than 40 kg body weight or dose increments of 25 mg or 50 mg for patients >40 kg body weight after a minimum of 2 days since the last dose increase.

5 mg per kg body weight given every 12 hours. 5 mg/kg), as deemed by the prescribing physician. e. 250 mg given every 12 hours should not be exceeded. 0 mg/kg. 2). 2). The safety and efficacy of this product in children below 6 years of age has not yet been established.

Therefore this product is not recommended for use in this population. Method of administration This product is for oral use. This product has to be taken whole, not divided or chewed, to ensure that the prolonged-release mechanism is maintained.

This product should be taken with sufficient liquid. This product can be taken with or without food. Treatment goals and discontinuation Before initiating treatment with tapentadol, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines.

During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no […]

The adverse drug reactions that were experienced by patients in the placebo controlled trials performed with this product were predominantly of mild and moderate severity. The most frequent adverse drug reactions were in the gastrointestinal and central nervous system (nausea, dizziness, constipation, headache and somnolence).

The table below lists adverse drug reactions that were identified from clinical trials performed with tapentadol prolonged-release products. They are listed by class and frequency. Frequencies are defined as very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1,000, <1/100); rare (≥1/10,000, <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).

ADVERSE DRUG REACTIONS FrequencySystem Organ Class Very common Common Uncommon Rare Unknown Immune system disorders Drug hypersensitivity* Metabolism and nutrition disorders Decreased appetite Weight decreased Psychiatric disorders Anxiety, Depressed mood, Sleep disorder, Nervousness, Restlessness Disorientation, Confusional state, Agitation, Perception disturbances, Abnormal dreams, Euphoric mood Drug dependence, Thinking abnormal Delirium** Nervous system disorders Dizziness, Somnolence, Headache Disturbance in attention, Tremor, Muscle contractions involuntary Depressed level of consciousness, Memory impairment, Mental impairment, Syncope, Sedation, Balance disorder, Dysarthria, Hypoaesthesia, Paraesthesia Convulsion, Presyncope, Coordination abnormal Eye disorders Visual disturbance Cardiac disorders Heart rate increased, Heart rate decreased Vascular disorders Flushing Blood pressure decreased Respiratory, thoracic and mediastinal disorders Dyspnoea Respiratory depression Gastrointestinal disorders Nausea, Constipation Vomiting, Diarrhoea, Dyspepsia Abdominal discomfort Impaired gastric emptying Skin and subcutaneous tissue disorders Pruritus, Hyperhidrosis, Rash Urticaria Renal and urinary disorders Urinary hesitation, Pollakiuria Reproductive system and breast disorders Sexual dysfunction General disorders and administration site conditions Asthenia, Fatigue, Feeling of body temperature change, Mucosal dryness, Oedema Drug withdrawal syndrome, Feeling abnormal, Irritability Feeling drunk, Feeling of relaxation * Post-marketing rare events of angioedema, anaphylaxis and anaphylactic shock have been reported.

** Post marketing cases of delirium were observed in patients with additional risk factors such as cancer and advanced age. Clinical trials performed with tapentadol prolonged-release tablets with patient exposure up to 1 year have shown little evidence of withdrawal symptoms upon abrupt discontinuations and these were generally classified as mild, when they occurred.

2) and treat patients accordingly should they occur. The risk of suicidal ideation and suicides committed is known to be higher in patients suffering from chronic pain. In addition, substances with a pronounced influence on the monoaminergic system have been associated with an increased risk of suicidality in patients suffering from depression, especially at the beginning of treatment.

For tapentadol data from clinical trials and post-marketing reports do not provide evidence for an increased risk. Drug dependence Repeated use of tapentadol can lead to drug dependence, even at therapeutic doses. 4). Paediatric population Frequency, type and severity of adverse reactions in children and adolescents treated with this product are expected to be the same as in adults treated with this product.

No new safety issues have been identified from completed paediatric trial for any of the age subgroups investigated. Limited clinical trial data on withdrawal symptoms in children using PR formulation of tapentadol are available. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.

It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

Tolerance and Opioid Use Disorder (abuse and dependence) Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as tapentadol. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD.

Abuse or intentional misuse of opioids may result in overdose and/or death. g. major depression, anxiety and personality disorders). 2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

g. too early requests for refills). This includes the review of concomitant opioids and psycho- active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Drug withdrawal syndrome Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with tapentadol. Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction.

When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months. The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations.

Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.

If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome. Hyperalgesia Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain.

This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality.

Symptoms of hyperalgesia may resolve with a reduction of opioid dose. Risk from concomitant use of sedating medicinal products such as benzodiazepines or related substances Concomitant use of this product and sedating medicinal products such as benzodiazepines or related substances may result in sedation, respiratory depression, coma and death.

Because of these risks, concomitant prescribing with these sedating medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe this product concomitantly with sedating medicinal products, the reduction of dose of one or both agents should be considered and the duration of the concomitant treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. 5). Respiratory Depression At high doses or in mu-opioid receptor agonist sensitive patients, this product may produce dose-related respiratory depression.

Therefore, this product should be administered with caution to patients with impaired respiratory functions. Alternative non-mu-opioid receptor agonist analgesics should be considered and this product should be employed only under careful medical supervision at the lowest effective dose in such patients.

9). Head Injury and Increased Intracranial Pressure This product should not be used in patients who may be particularly susceptible to the intracranial effects of carbon dioxide retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma.

Analgesics with mu-opioid receptor agonist activity may obscure the clinical course of patients with head injury. This product should be used with caution in patients with head injury and brain tumours. Seizures This product has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical trials.

However, like other analgesics with mu-opioid agonist activity this product should be prescribed with care in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. 5). 2). 5-fold increase in systemic exposure, respectively, compared with subjects with normal hepatic function.

2), especially upon initiation of treatment. This product has not been studied in patients with severe […]

e. 5)